NASDAQ:TSHA

Taysha Gene Therapies (TSHA) Stock Forecast, Price & News

$0.79

+0.04 (+5.33%)

(As of 06/2/2023 ET)

Compare

Today's Range: $0.73
▼
$0.79
50-Day Range: $0.64
▼
$0.87
52-Week Range: $0.61
▼
$5.09

Volume: 283,913 shs
Average Volume: 255,682 shs
Market Capitalization: $50.70 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.46

Taysha Gene Therapies MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.71 Rating Score
Upside/Downside: 941.9% Upside
$8.23 Price Target
Short Interest: Healthy
3.23% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$3,400 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.87) to ($0.48) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.52 out of 5 stars

Medical Sector

121st out of 983 stocks

Biological Products, Except Diagnostic Industry

15th out of 164 stocks

4.4

Analyst's Opinion

Consensus Rating
Taysha Gene Therapies has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 10 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.23, Taysha Gene Therapies has a forecasted upside of 941.9% from its current price of $0.79.
Amount of Analyst Coverage
Taysha Gene Therapies has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

5.0

Short Interest

Percentage of Shares Shorted
3.23% of the float of Taysha Gene Therapies has been sold short.
Short Interest Ratio / Days to Cover
Taysha Gene Therapies has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Taysha Gene Therapies has recently decreased by 31.21%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Taysha Gene Therapies does not currently pay a dividend.
Dividend Growth
Taysha Gene Therapies does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TSHA.

0.0

News and Social Media Coverage

Search Interest
Only 2 people have searched for TSHA on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Taysha Gene Therapies to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Taysha Gene Therapies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,400.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
13.20% of the stock of Taysha Gene Therapies is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
45.12% of the stock of Taysha Gene Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Taysha Gene Therapies are expected to grow in the coming year, from ($0.87) to ($0.48) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Taysha Gene Therapies is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Taysha Gene Therapies is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Taysha Gene Therapies (NASDAQ:TSHA) Stock

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.

Receive TSHA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Taysha Gene Therapies and its competitors with MarketBeat's FREE daily newsletter.

TSHA Stock News Headlines

May 20, 2023 | americanbankingnews.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Rating of "Moderate Buy" by Analysts

May 19, 2023 | finance.yahoo.com

Taysha Gene Therapies Touts Encouraging Preclinical Data From Rett Syndrome Candidate

June 3, 2023 | Vantage Point (Ad)

We Called (ARWR) In Advance, Which Stocks Are Next?

Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.

May 19, 2023 | finance.yahoo.com

Taysha Gene Therapies Presents Preclinical Data on TSHA-102 for Rett Syndrome Demonstrating Cellular Regulation of MeCP2 Expression in Key Mouse Models at the American Society of Gene and Cell Therapy 26th Annual Meeting

May 16, 2023 | finance.yahoo.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2023 Earnings Call Transcript

May 15, 2023 | markets.businessinsider.com

Robert W. Baird Sticks to Its Buy Rating for Taysha Gene Therapies (TSHA)

May 12, 2023 | markets.businessinsider.com

JMP Securities Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA)

May 12, 2023 | finance.yahoo.com

Q1 2023 Taysha Gene Therapies Inc Earnings Call

June 3, 2023 | Vantage Point (Ad)

We Called (ARWR) In Advance, Which Stocks Are Next?

May 11, 2023 | finance.yahoo.com

Taysha Gene Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 7, 2023 | americanbankingnews.com

Head-To-Head Contrast: Taysha Gene Therapies (NASDAQ:TSHA) and Sorrento Therapeutics (NASDAQ:SRNE)

May 4, 2023 | finance.yahoo.com

Taysha Gene Therapies to Release First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11

April 29, 2023 | americanbankingnews.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Short Interest Down 15.5% in April

April 27, 2023 | bizjournals.com

Ouch! Another gene therapy setback as biotech halts 200-job Durham facility

April 27, 2023 | bizjournals.com

Another gene therapy setback as biotech halts 200-job Durham facility

April 27, 2023 | finance.yahoo.com

Taysha Gene Therapies Announces Presentation on New Preclinical Data for TSHA-102 in Rett Syndrome at Upcoming American Society of Gene and Cell Therapy 26th Annual Meeting

April 25, 2023 | americanbankingnews.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

April 18, 2023 | americanbankingnews.com

Short Interest in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Declines By 18.2%

April 15, 2023 | finance.yahoo.com

Even after rising 30% this past week, Taysha Gene Therapies (NASDAQ:TSHA) shareholders are still down 84% over the past year

April 5, 2023 | americanbankingnews.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Recommendation of "Moderate Buy" by Brokerages

April 2, 2023 | americanbankingnews.com

JMP Securities Reaffirms Market Outperform Rating for Taysha Gene Therapies (NASDAQ:TSHA)

April 2, 2023 | americanbankingnews.com

Taysha Gene Therapies, Inc. Expected to Post Q1 2023 Earnings of ($0.39) Per Share (NASDAQ:TSHA)

April 1, 2023 | americanbankingnews.com

Chardan Capital Trims Taysha Gene Therapies (NASDAQ:TSHA) Target Price to $5.00

April 1, 2023 | americanbankingnews.com

Truist Financial Lowers Taysha Gene Therapies (NASDAQ:TSHA) Price Target to $3.00

March 31, 2023 | americanbankingnews.com

Taysha Gene Therapies (NASDAQ:TSHA) Rating Reiterated by Needham & Company LLC

March 30, 2023 | americanbankingnews.com

Cantor Fitzgerald Lowers Taysha Gene Therapies (NASDAQ:TSHA) Price Target to $2.00

March 29, 2023 | markets.businessinsider.com

Chardan Capital Keeps Their Buy Rating on Taysha Gene Therapies (TSHA)

See More Headlines

TSHA Price History

30 days | 90 days | 365 days | Advanced Chart

TSHA Company Calendar

Last Earnings: 3/28/2023
Today: 6/03/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TSHA
CUSIP: N/A
CIK: 1806310
Web: www.tayshagtx.com
Phone: 214-612-0000
Fax: N/A
Employees: 38
Year Founded: 2020

Price Target and Rating

Average Stock Price Forecast: $8.23
High Stock Price Forecast: $19.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +971.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.71
Research Coverage: 14 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.75)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-166,010,000.00
Net Margins: N/A
Pretax Margin: -1,849.60%
Return on Equity: -1,790.06%
Return on Assets: -110.88%

Debt

Debt-to-Equity Ratio: 40.01
Current Ratio: 1.33
Quick Ratio: 1.33

Sales & Book Value

Annual Sales: $2.50 million
Price / Sales: 20.28
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.23) per share
Price / Book: -3.43

Miscellaneous

Outstanding Shares: 64,180,000
Free Float: 55,707,000
Market Cap: $50.70 million
Optionable: Not Optionable
Beta: 1.17

Social Links

Key Executives

Mr. R. A. Session II (Age 43)
Founder, Pres, CEO & Director
Comp: $542.95k

Mr. Kamran Alam CPA (Age 44)
M.B.A., Chief Financial Officer
Comp: $395.51k

Dr. Suyash Prasad FFPM (Age 52)
M.Sc., MBBS, M.D., M.B.B.S., F.F.P.M, Chief Medical Officer and Head of R&D
Comp: $617.34k

Mr. Frederick Porter Ph.D.
Chief Technical Officer

Mr. Jim Rouse
Chief Information Officer

Ms. Tracy M. Porter
Chief People Officer

Ms. Emily McGinnis M.P.H.
Chief Patient Officer & Head of Gov. Affairs

Ms. Mishima Gerhart
Chief Regulatory Officer & Head of Quality

Mr. Sean McAuliffe
Chief Commercial Officer

Mr. Greg Gara
Sr. VP of Manufacturing

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TSHA Stock - Frequently Asked Questions

Should I buy or sell Taysha Gene Therapies stock right now?: 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taysha Gene Therapies in the last twelve months. There are currently 4 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TSHA shares.
View TSHA analyst ratings or view top-rated stocks.
What is Taysha Gene Therapies' stock price forecast for 2023?: 14 brokerages have issued 12-month price targets for Taysha Gene Therapies' shares. Their TSHA share price forecasts range from $2.00 to $19.00. On average, they expect the company's share price to reach $8.23 in the next year. This suggests a possible upside of 941.9% from the stock's current price.
View analysts price targets for TSHA or view top-rated stocks among Wall Street analysts.
How have TSHA shares performed in 2023?: Taysha Gene Therapies' stock was trading at $2.26 at the start of the year. Since then, TSHA shares have decreased by 65.0% and is now trading at $0.79.
View the best growth stocks for 2023 here.
Are investors shorting Taysha Gene Therapies?: Taysha Gene Therapies saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 1,190,000 shares, a drop of 31.2% from the April 30th total of 1,730,000 shares. Based on an average trading volume of 401,900 shares, the short-interest ratio is currently 3.0 days. Currently, 3.2% of the company's stock are short sold.
View Taysha Gene Therapies' Short Interest.
When is Taysha Gene Therapies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our TSHA earnings forecast.
How were Taysha Gene Therapies' earnings last quarter?: Taysha Gene Therapies, Inc. (NASDAQ:TSHA) announced its quarterly earnings data on Tuesday, March, 28th. The company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.41) by $0.58. The company had revenue of $2.50 million for the quarter.

When did Taysha Gene Therapies IPO?: (TSHA) raised $125 million in an initial public offering (IPO) on Thursday, September 24th 2020. The company issued 6,600,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies served as the underwriters for the IPO and Chardan was co-manager.
What is Taysha Gene Therapies' stock symbol?: Taysha Gene Therapies trades on the NASDAQ under the ticker symbol "TSHA."
Who are Taysha Gene Therapies' major shareholders?: Taysha Gene Therapies' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (4.81%), Acadian Asset Management LLC (0.63%), BlackRock Inc. (0.62%), Geode Capital Management LLC (0.59%), Quantum Private Wealth LLC (0.56%) and Renaissance Technologies LLC (0.39%). Insiders that own company stock include Kamran Alam, Paul B Manning, Phillip B Donenberg, RA Session II, Sean P Nolan, Sukumar Nagendran and Suyash Prasad.
View institutional ownership trends.
How do I buy shares of Taysha Gene Therapies?: Shares of TSHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Taysha Gene Therapies' stock price today?: One share of TSHA stock can currently be purchased for approximately $0.79.
How much money does Taysha Gene Therapies make?: Taysha Gene Therapies (NASDAQ:TSHA) has a market capitalization of $50.70 million and generates $2.50 million in revenue each year. The company earns $-166,010,000.00 in net income (profit) each year or ($2.75) on an earnings per share basis.
How can I contact Taysha Gene Therapies?: Taysha Gene Therapies' mailing address is 2280 Inwood Road, DALLAS TX, 75235. The official website for the company is www.tayshagtx.com. The company can be reached via phone at 214-612-0000 or via email at investors@tayshagtx.com.

This page (NASDAQ:TSHA) was last updated on 6/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial